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Abstract
Objectives: The aim of the current study was to describe a method that assesses the hyperemic microvascular blood plasma
volume of the calf musculature. The reversibly albumin binding contrast agent gadofosveset was used in dynamic contrast-
enhanced magnetic resonance imaging (DCE MRI) to assess the microvascular status in patients with peripheral arterial
disease (PAD) and healthy controls. In addition, the reproducibility of this method in healthy controls was determined.
Materials and Methods: Ten PAD patients with intermittent claudication and 10 healthy control subjects were included.
Patients underwent contrast-enhanced MR angiography of the peripheral arteries, followed by one DCE MRI examination of
the musculature of the calf. Healthy control subjects were examined twice on different days to determine normative values
and the interreader and interscan reproducibility of the technique. The MRI protocol comprised dynamic imaging of
contrast agent wash-in under reactive hyperemia conditions of the calf musculature. Using pharmacokinetic modeling the
hyperemic fractional microvascular blood plasma volume (Vp, unit: %) of the anterior tibial, gastrocnemius and soleus
muscles was calculated.
Results: Vp was significantly lower for all muscle groups in PAD patients (4.361.6%, 5.063.3% and 6.163.6% for anterior
tibial, gastrocnemius and soleus muscles, respectively) compared to healthy control subjects (9.162.0%, 8.961.9% and
9.362.1%). Differences in Vp between muscle groups were not significant. The coefficient of variation of Vp varied from 10–
14% and 11–16% at interscan and interreader level, respectively.
Conclusions: Using DCE MRI after contrast-enhanced MR angiography with gadofosveset enables reproducible assessment
of hyperemic fractional microvascular blood plasma volume of the calf musculature. Vp was lower in PAD patients than in
healthy controls, which reflects a promising functional (hemodynamic) biomarker for the microvascular impairment of
macrovascular lesions.
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Introduction
Functional measurements in peripheral arterial disease (PAD)
are used for diagnostic purposes and for quantifying the
hemodynamic consequences of obstructive arterial lesions
[1,2,3,4]. Among these functional measurements, the ankle
brachial index (ABI) is the most recognized and widely applied
test for diagnosis and therapy monitoring in PAD
[1,2,3,4,5,6,7,8,9]. ABI measurements only represent macrovas-
cular functionality, whereas PAD is known to affect the
microcirculation as well, particularly in patients with diabetes
[10,11]. Functional assessment of the microvascular status of the
lower extremities could therefore be a valuable addition to the
current diagnostic work-up in PAD to objectively determine
disease severity and might be useful in evaluation of therapeutic
efficacy in PAD [12,13,14,15]. MRI is well-suited for compre-
hensive diagnostic imaging of both macrovascular morphology of
the peripheral vascular tree using contrast-enhanced MRA (CE-
MRA) [16,17,18] and the microvascular functionality by dynamic
contrast-enhanced (DCE) MRI [14,19,20,21].
Commonly used functional measures in DCE MRI are the rate
constant (k) and the transfer constant (K
trans), which both describe
the wash-in of a contrast agent. These measures reflect a combi-
nation of the rate of microvascular reactivity and permeability,
both of which may be significantly impaired in patients with PAD
[14,19,22,23]. The rate of vascular reactivity, as determined by
rate constant k and transfer constant K
trans, however, decreases with
age, mainly due to slow progression of vascular resistance as
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ratio [24]. Therefore, the clinical relevance of these measures in
PAD patients is questionable. In mild PAD, i.e. intermittent
claudication, symptoms generally arise and progress slowly during
exercise (impaired active hyperemia). Critical ischemia, on the
other most severe end of the pathophysiological spectrum, is
a chronic condition characterized by hypoperfusion of the distal
lower extremity at rest. It is conceivable that in both of these
conditions, the absolute degree of microvascular dilatation, rather
than its rate, is of more clinical relevance and a better reflection of
clinical severity of microvascular disease in PAD compared to rate
and transfer constants. We hypothesize that maximum microvas-
cular dilatation can be assessed by determining the hyperemic
fractional microvascular blood plasma volume (Vp) using DCE
MRI. Microvascular blood plasma volume, however, is hard or
even impossible to measure using extracellular contrast agents, as
clinically applied low-molecular weight (i.e. small-sized) contrast
agents extravasate rather rapdily into the interstitial space
[22,25,26]. Recently introduced blood pool agents are largely
prevented from leaking into the interstitial space by a strong,
reversible albumin binding and therefore theoretically allow
a more reliable assessment of microvascular blood plasma volume
with DCE MRI [27,28].
The main purpose of the current study was to describe a method
to assess hyperemic microvascular blood plasma volume of the calf
musculature and to investigate its ability to discriminate between
PAD patients and healthy control subjects using the blood pool
contrast agent gadofosveset in dynamic contrast-enhanced (DCE)
MRI. Also, the interreader and interscan reproducibility of this
method was determined in healthy control subjects.
Materials and Methods
Study Population
Ten patients (age mean 6 SD: 66.569.9 years; 8 males and
2 females) with proven PAD (intermittent claudication, Fontaine
stage II, [5]), diagnosed by the vascular surgeon, and 10 healthy
control subjects without signs and symptoms of PAD (age
24.162.2 years; 3 males and 7 females) were included in this
study. Exclusion criteria were diabetes mellitus, hemodynamic
instability, contra-indications for MRI (i.e. claustrophobia, known
gadolinium based contrast agent allergy, and estimated glomular
filtration rate ,30 mL/kg/1.73 m
2. The institutional medical
ethics committee approved the study and all subjects gave written
informed consent before inclusion.
MRI Protocol
An overview of the imaging protocol is given in figure S1. The
entire DCE MRI examination lasted approximately 15 minutes.
All scans were performed on a 1.5-T commercially available MRI
system (Intera, Philips Medical Systems, Best, The Netherlands).
For all acquisitions a dedicated 12-element three-station periph-
eral vascular phased-array coil (4 elements/station) was used.
Subjects were imaged in the supine position and care was taken
not to deform calf muscle by calf-bed contact. All subjects were
lying in this position for at least 30 minutes before the DCE MRI
measurement was started. During this time a conventional three-
station contrast enhanced MR angiography (CE-MRA) exam was
performed in the subject. Therefore, prior to the start of the DCE
MRI measurement, all subjects had already received 8 mL of
gadofosveset (AblavarH, Lantheus Medical Imaging, Billerica,
MA).
PAD patients were examined once, whereas in healthy control
subjects the entire exam was repeated on a different day (interval
mean 6 SD: 9.363.5 days) to determine normative values and the
reproducibility of the technique.
Survey. A non-enhanced time-of-flight (TOF) scan of the
pelvic, upper and lower leg station was acquired to prescribe the
imaging volumes of interest for subsequent morphological and
functional imaging. A turbo field echo (TFE) pulse sequence was
used with a 180u inversion prepulse to suppress stationary tissues.
Thirty-one transverse slices per station were acquired with 3.3-mm
slice thickness and 11-mm interslice gap, and an inferiorly
concatenated saturation band. The standard quadrature body
coil was used for signal transmission and reception. For positioning
of the 3D angiography volumes, maximum intensity projections
(MIP) were generated in 3 orthogonal directions.
CE-MRA. A three-station 3D CE-MRA was performed as
previously described [29]. Prior to contrast medium administra-
tion, a non-enhanced ‘mask’ image data set was acquired with
exactly the same acquisition parameters as the CE-MRA, enabling
background tissue suppression by image subtraction.
DCE MRI. A dynamic 3D T1-weighted spoiled gradient echo
sequence was used for DCE MRI with the following acquisition
parameters: TR 8.0 ms, TE 0.91 ms, flip angle 30u, FOV
400 mm, matrix 1286128, NSA 1 and a parallel imaging
(SENSE) reduction factor of 2 (right-left direction). Slice thickness
was 6.00 mm; 12 transverse slices were imaged. Acquired voxel
dimensions were 3.1363.1366.00 mm. Dynamic scan time was
2.6 seconds. Slices were centered at the maximum diameter of the
calf. A series of 80 dynamic scans were acquired in approximately
3.5 minutes. A cuff paradigm was applied to provoke reactive
hyperemia [14,30]. A fixed dose of 2 mL gadofosveset was injected
directly after cuff inflation, using an automated power injector
(Medrad Spectris, Indianola, PA). Cuff inflation was directly
followed by contrast injection to allow systemic contrast equili-
bration in the arterial blood pool during cuff compression and to
ensure that DCE MRI data were acquired during the steady state,
at which gadofosveset was maximally bound to albumin
[27,28,31]. The acquisition started 330 seconds after cuff inflation.
The cuff was then rapidly deflated at the start of the 6
th dynamic
scan.
Before the cuff inflation of the dynamic sequence, a series of
spoiled fast gradient echo scans with identical contrast and
geometry parameters with respect to the dynamic sequence, but
with varying flip angles (2, 5, 10, 15, 25 and 35u) were acquired
(figure S1). These variable flip angle scans were used for T1
baseline determination (after contrast agent administration for CE-
MRA) and subsequent conversion of signal changes to T1
relaxation time changes and contrast agent concentration time-
courses [12,32].
Image Analysis
Only the most symptomatic leg was analyzed in patients,
whereas for healthy control subjects the measures were determined
for both legs separately and subsequently averaged. Two in-
dependent MRI readers, blinded for each other’s results and
acquisition order, analyzed the data sets of healthy control
subjects. Patient datasets were analyzed by one observer,
foreshadowing the good interreader reproducibility we found in
healthy control subjects, which were concordant to previous results
[33].
The image software application MRIcro (MRIcro, http://www.
mricro.com/) was used to manually draw regions of interest
(ROI’s) of 363 pixels in the anterior tibial, gastrocnemius and
soleus muscles for all 12 slices, resulting in a ROI volume of
6.3 mL. Also, a larger ROI covering the entire cross-section of the
calf musculature in four successive slices was drawn. These ROI’s
DCE-MRI Assessment of Microvascular Blood Volume
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volume due to large variations in calf size in the subjects. An
arterial ROI was drawn within the tibiofibular trunk to obtain the
arterial input function (AIF). Self-written software code (Matlab,
The Mathworks inc., Natick, MA) was used for the analysis of T1-
weighted signal intensity time-courses for each ROI. Matlab was
also used to calculate the functional microvascular parameters as
represented by figure S1.
The T1-value, prior to the contrast injection of the DCE-MRI
but after that of the CE-MRA, were determined from the variable
flip angle series for each ROI [34]. To calculate the T1-value, the
signal curve as a function of the flip angle was fitted to the signal
formula for the spoiled fast gradient echo pulse sequence using
a non-linear (Levenberg-Marquardt) optimization algorithm,
which corrects for the inherent non-linearity in the relation
between changes in MRI signal, T1, and contrast agent
concentration. Any possible T2* effects were negated by the short
TE used. The dynamic sequence was used to calculate the
following functional measures: hyperemic fractional microvascular
blood plasma volume (Vp, unit: %), rate constant (k, unit: min
21)
and the area-under-the-curve in the first 90 seconds after contrast
arrival (AUC90s, unit: mM?s). Individual signal time-courses were
normalized with respect to resting values, measured prior to
contrast agent arrival and converted to contrast agent concentra-
tion, using the relation between T1 relaxation time and the signal
intensity for a spoiled gradient echo pulse sequence [12].
The concentration time-course in muscle tissue Ct(t)after cuff
deflation was empirically modeled by the relation
Ct(t)~VpCmax
p (1{e{kt)e{mt
where Vp is the fractional hyperemic blood plasma volume in
muscle tissue, Cmax
p is the maximum concentration of contrast
agent in blood, k is the rate constant describing the speed of muscle
enhancement after cuff deflation, and m represents the tissue
clearance rate. The parameters Vp and k were calculated by non-
linear curve fitting, using a Levenberg-Marquadt optimization
algorithm [35]. Cmax
p was determined from the asymptotic
concentration level in the femoral artery. The concentration
time-courses were used to calculate the area-under-curve for the
first 90 seconds after cuff deflation (AUC; mMs). The functional
measure Vp is related to the degree of (total) microvascular
dilatation, whereas the functional measures k and AUC reflect the
rate of microvascular reactivity.
Statistical Analysis
A two-samples t-test was used to determine the significance of
differences in the functional parameters between patients and
healthy control subjects. P,0.05 was considered statistically
significant. Statistical analysis was performed with commercially
available statistical software (SPSS 16.0, SPSS Inc., Chicago, IL).
For healthy control subjects the reproducibility of the measures
was calculated, both at interscan and interreader level. Re-
producibility of each parameter was expressed as coefficient of
variation (CV in %) and the repeatability coefficient (RC). The CV
is derived by dividing overall mean within-subject standard
deviation (SDws) by the mean measurement value over all subjects.
The RC is the smallest noticeable difference that can be detected
beyond measurement error and is defined as 1.96?!2?SDws
[36,37].
Assuming that interscan reproducibility was mainly influenced
by scan and time related varariabilities (e.g. variations in slice
positioning and day-to-day variations in physiology) it was
calculated by averaging results of both MRI readers for each
scan (mean of MRI 1 for reader A and B versus the mean of MRI
2 for reader A and B). Conversely, interreader reproducibility is an
indicator of the image reading error (e.g. positioning and
delineation of ROI’s) and is primarily influenced by reader
experience. Interreader reproducibility was calculated by averag-
ing the results of both scans for each MRI reader (mean of reader
A for MRI 1 and MRI 2 versus the mean of reader B for MRI 1
and MRI 2).
Results
All included subjects underwent DCE MRI as planned without
experiencing side effects or adverse events.
CE-MRA
CE-MRA revealed stenosis (.50%) of the SFA in 6 out of 10
patients, whereas an occlusion of the SFA was found in the
remaining 4 patients. In 3 out of 10 patients there were slight
vessel wall irregularities in the iliac arteries. The remaining
patients had no signs of obstructive lesions in the iliac arteries. At
least 2 out of 3 main arteries of the lower leg were free from
obstructive lesions in all patients. CE-MRA revealed no signs of
PAD in any of the control subjects.
DCE MRI
Examples of DCE MRI derived time-courses of the entire cross-
section of the calf musculature and arterial blood are presented in
figure S2. Muscle tissue enhancement was generally less strong in
patients compared to healthy control subjects (figure S2). Signal
time-courses of the individual muscle groups showed similar
results. Strongest enhancement was found in the soleus muscle.
An AIF was obtained for each individual subject within the most
prominent arterial structure visible, which was either the
tibiofibular trunk or posterior tibial artery in most patients.
Quality of the AIF was lower in patients in comparison with the
AIF of healthy control subjects. There was a trend (p=0.07)
towards higher maximum concentration of the AIF in patients
compared to the healthy control subjects.
Patients Versus Healthy Control Subjects
Table S1 lists the values of DCE MRI measures obtained in
patients and healthy control subjects. Vp was significantly lower for
all muscle groups in PAD patients compared to healthy control
subjects. Differences in Vp between patients and controls ranged
from 3.2–4.8% (p,0.01). For both patients and controls the
differences in Vp between muscle groups were not significant
(p=0.49 and p=0.15, respectively). Vp of the entire cross-section
of the calf musculature was significantly higher compared to the Vp
of individual muscle groups, both for patients and healthy control
subjects (p,0.01). The rate constant k was significantly lower in
PAD patients for all muscle groups (range differences 5.5–
7.9 min
21,p ,0.01). The AUC only was significantly lower in
PAD patients for the anterior tibial muscle (p,0.01). Vp,kor AUC
were not consistently higher or lower in PAD patients with stenosis
(n =6) compared to PAD patients with an occlusion (n=4) of the
SFA.
Reproducibility
Values and reproducibility measures of the pre-contrast T1
assessment in healthy control subjects are given in table S2. T1
assessment showed interscan and interreader CV’s below 6 and
7% respectively.
DCE-MRI Assessment of Microvascular Blood Volume
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control subjects is listed in table S3. CV and RC of Vp for the
different muscle groups were below 17% and 6%, respectively, at
interscan level and below 16% and 6%, respectively, at interreader
level. Interreader and interscan reproducibility of Vp were
comparable for most muscle groups. Reproducibility values of Vp
were comparable for the different muscles. Interscan reproduc-
ibility of k and AUC showed CV values as high as 49% and 37%,
respectively. Interreader reproducibility was markedly better with
a maximum CV of 22% and 27% for k and AUC, respectively.
Interreader CV was lowest for the entire muscle group (8.4% and
1.8% for k and AUC, respectively).
Discussion
In this study we found that gadofosveset, a reversible albumin
binding (blood pool) contrast agent, can be used in DCE MRI to
reproducibly determine a functional surrogate of the hyperemic
microvascular blood plasma volume in the calf. Using this
functional measure, the fractional microvascular blood plasma
volume Vp, patients with PAD revealed a reduced Vp for all muscle
types in the calf relative to healthy controls. Moreover, patients
with PAD could be discriminated from healthy subjects on the
basis of Vp. Measures that quantified the rate of vasodilation (k and
AUC) were also reduced in patients with PAD compared to
healthy controls. However, interscan and interreader reproduc-
ibility of Vp were better compared to those of measures that reflect
the vasodilation rate (k and AUC). We also found that functional
DCE MRI with a blood pool contrast agent can easily be
combined with clinical CE-MRA to assess both macrovascular
morphology and microvascular functionality in patients with PAD.
Pathophysiologic Effect in PAD
The fractional microvascular blood plasma volume Vp of the calf
musculature in PAD patients with intermittent claudication was
significantly lower than in healthy control subjects. A lower Vp in
patients with PAD can possibly be explained by impaired
microvascular dilatative capacity, which is the result of endothelial
dysfunction [38,39,40,41,42,43]. This means that DCE MRI can
be used to determine the fractional microvascular blood plasma
volume of each large muscle group of the calf and as such can
identify patients with reduced Vp as compared to healthy controls.
Vp did show consistent differences between PAD patients with
stenosis or occlusions. This can be explained partly by the small
sample size (respectively six PAD patients with stenosis and four
with occlusion of the SFA), but also by the fact that most of the
patients with an occlusion of the SFA revealed well developed
collateral arteries at CE-MRA and both patients with stenosis and
occlusion had the same clinical symptoms (i.e. intermittent
claudication).
There were no significant differences between individual muscle
groups within patients or controls. This indicates that this method
does not distinguish different muscles of the calf. In healthy control
subjects, Vp of the entire cross-section of the calf musculature
showed significantly higher values when compared to Vp of the
individual muscles. In patients a similar trend was observed. A
higher Vp for the entire cross-section of the calf musculature can be
explained by the inclusion of relatively large arterial and venous
structures (in comparison to microvessels) in these regions of
interest, increasing the average amount of contrast agent within
the ROI which results in a higher Vp. To avoid relatively large
blood vessels, assessment of Vp of individual muscles is preferred
over the Vp of the entire cross-section of the calf musculature.
The measures k and the AUC both reflect the initial speed of
signal enhancement during reactive hyperemia and were lower in
patients compared to healthy controls. This finding indicates lower
vascular reactivity in patients with PAD, which is in line with the
results of previous studies [14,19].
Reproducibility
Interscan reproducibility of Vp in DCE MRI was good
compared to k and the AUC. The interscan CV in healthy control
subjects of all muscle groups was lower than the relative difference
between patients and healthy control subjects. This implies that
the reproducibility of the measurement is sufficient to discriminate
patients with PAD from healthy controls. The RC for the anterior
tibial and gastrocnemius muscles was lower compared to the
absolute difference between patients and healthy controls. The RC
for the entire cross-section of the calf musculature and the soleus
muscle was comparable to the absolute difference between patients
and healthy control subjects. A poor RC is probably the result of
our small study population and these results might improve with
a larger group of subjects.
Reproducibility of Vp was in general much higher than the
reproducibility of k and the AUC, both at interscan and interreader
level. This is clearly reflected by the large RC values for k and
AUC, which are comparable or even higher than the measured
values for k and AUC in healthy control subjects. These findings
are in line with those found by Galbraith et al. concerning the
extravasation rate constant K
trans, using low molecular weight (i.e.
small-sized) extracellular contrast agents [19]. For a blood pool
acting contrast agent, k mainly represents the speed of the filling of
the microvasculature in the time period of the measurement,
rather than the extravasation of contrast agent into the interstitial
space. This rapid filling phase did not prove reproducible and is
therefore not suitable as a monitoring measure in clinical practice.
T1 mapping showed good interscan and interreader reproduc-
ibility of T1 values for each muscle group. High interreader
reproducibility indicates that the technique is relative insensitive
for the exact location at which a ROI is drawn within a muscle
group and that the technique is highly reader-independent. This is
especially desirable for monitoring purposes, as in clinical routine
it is likely that follow-up examinations will be assessed by different
readers. Good reproducibility of T1 mapping suggests that our
scan and analysis method is reliable and that the moderate
reproducibility we found for Vp is the result of biologic factors and/
or the cuff paradigm.
Clinical Relevance
Functional assessment of muscle perfusion of the lower
extremities with dynamic contrast-enhanced (DCE) MRI, could
be a valuable addition to the diagnostic work-up in PAD to
objectively determine disease severity. An added advantage is that
DCE MRI can be combined with the standard morphological
assessment of PAD with CE-MRA. Also, DCE-MRI could be of
value in non-invasive assessment of the efficacy of novel
therapeutic strategies such as stem cell and gene therapy. DCE
MRI of calf musculature may indicate the contribution of
macrovascular blood flow on muscle perfusion and provide an
objective diagnostic tool to determine the influence and severity of
microvascular dysfunction in PAD [13,14,15,19].
Commonly used extracellular contrast agents rapidly extrava-
sate into the interstitial space and are therefore less suitable to
determine biomarkers of the microvascular blood plasma volume
[25].
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Although we found large differences between patients with PAD
and healthy control subjects for Vp and the reproducibility of Vp
was good, the number of subjects in this study is relatively small
and further research will be needed to confirm our results by
blinded analysis in more patients and compare them with age and
gender matched control subjects. The observed differences
between patients with PAD and the controls is expectedly smaller
for age-matched, thus older, controls. In addition, it would be
clinically relevant to include patients with different symptoms of
PAD to assess variations in the involvement of microvascular
impairment in PAD.
In all subjects a three-station CE-MRA of the peripheral arteries
was performed, prior to the DCE MRI. For CE-MRA the first
bolus injection of gadofosveset was used. This means all subjects
already had gadofosveset in their systemic circulation at the start of
the DCE MRI. The residual presence of contrast agent in the
circulation affects the T1 determination and its variability.
However, a combination of both exams is highly desirable for
clinical practice and our results prove the possibility to discrim-
inate patients from control subjects and provided good re-
producibility of Vp (and T1), despite the previous bolus injection
for angiography.
Although in reality a small fraction (615%) of unbound
gadosfosveset is available for extravasation into the interstitial
space, the influence of this fraction upon the outcome can be
neglected as the relative relaxivity of albumin-bound gadofosveset
is much higher compared to the unbound fraction (r1 of
respectively 19 and 5.2 L?mmol
21?s
21 in blood plasma at 37uC
at 1.5 T) and the total fraction of albumin-bond gadofosveset
(685%) is much larger as compared to the unbound fraction
[27,28,31]. In this study, gadofosveset proved to be a usable
contrast agent for DCE MRI of muscle tissue in PAD to obtain
a surrogate functional measure of microvascular blood plasma
volume in patients with PAD.
Conclusion
DCE MRI after CE-MRA using a blood pool contrast agent is
able to determine the hyperemic microvascular blood plasma
volume Vp of the calf musculature and to identify patients with
PAD as compared to healthy control subjects. In addition, the
reproducibility of Vp was good in healthy control subjects.
Together with the ability to acquire DCE MRI data combined
with CE-MRA during a single examination makes DCE MRI with
a blood pool acting agent a valuable addition to CE-MRA to
assess both the macrovascular morphology and functional
(hemodynamic) status of the calf microvasculature in patients
with PAD.
Supporting Information
Figure S1 Overview of the imaging protocol. DCE MRI was
preceded by conventional three-station contrast-enhanced MR
angiography (CE-MRA) for which a dose of 8 mL gadofosveset
was administered. CE-MRA was followed by ‘pre-contrast’ T1
determination. A 6-minute cuff compression of the thigh was used
to provoke reactive hyperemia within the calf musculature.
Directly after cuff inflation a single dose of 2 mL gadofosveset
was injected. Half a minute before cuff deflation the dynamic
contrast-enhanced (DCE) MRI was started.
(TIF)
Figure S2 Coronal maximum intensity projection (MIP) of a CE-
MRA examination of the peripheral arterial tree of a patient with
PAD (left panel) and examples of axial cross-sectional CE-MRA
and DCE images of a patient with PAD (center panel) and
a healthy control subject (right panel), respectively. The compar-
ison for DCE MRI between patients with PAD and healthy
control subjects was made for the tibial anterior (A), gastrocnemius
(B) and soleus (C) muscle, as well as the entire cross-section of the
calf musculature (area within the black dotted lines). The lower
center and right panels show representative examples of the
relative signal change in blood and the entire cross-section of the
calf musculature before and after cuff release in a patient with
PAD and healthy control, respectively.
(TIF)
Table S1 DCE MRI of the calf musculature in patients with
PAD and healthy control subjects Caption: values are represented
as mean 6 SD; Vp, fractional microvascular blood plasma volume;
k, rate constant; AUC90s, area under the curve for the first 90
seconds after cuff release.
*p,0.01,
** p,0.05.
(DOCX)
Table S2 Reproducibility of T1 determination in healthy
control subjects Caption: values are presented as mean 6 SD;
T1pre,T1 before administration of contrast agent; CV, coefficient of
variation; RC, repeatability coefficient.
*Pre-contrast T1 values
were actually obtained after a prior injection of 8 mL gadofosve-
set, as used for contrast-enhanced MR angiography of the lower
extremities.
(DOCX)
Table S3 Reproducibility of DCE MRI in healthy control
subjects Caption: values are presented as mean 6 SD; A,
maximum concentration; Vp, fractional microvascular blood
plasma volume; k, rate constant; AUC90s, area under the curve
for the first 90 seconds; CV, coefficient of variation; RC,
repeatability coefficient.
(DOCX)
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